Cell Reports
Volume 36, Issue 5, 3 August 2021, 109479
Journal home page for Cell Reports

Article
Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication

https://doi.org/10.1016/j.celrep.2021.109479Get rights and content
Under a Creative Commons license
open access

Highlights

  • VPS34 and fatty acid metabolism inhibitors impair SARS-CoV-2 growth

  • Post-entry steps in the SARS-CoV-2 replication cycle are impaired

  • The inhibitors alter SARS-CoV2 replication center morphology

  • Knockout of fatty acid synthase also impairs SARS-CoV-2 growth

Summary

Coronaviruses rely on host membranes for entry, establishment of replication centers, and egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways have previously shown promise as antivirals and are actively being pursued as treatments for other conditions. Here, we test small molecule inhibitors that target the PI3 kinase VPS34 or fatty acid metabolism for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity. Our studies determine that compounds targeting VPS34 are potent SARS-CoV-2 inhibitors. Mechanistic studies with compounds targeting multiple steps up- and downstream of fatty acid synthase (FASN) identify the importance of triacylglycerol production and protein palmitoylation as requirements for efficient viral RNA synthesis and infectious virus production. Further, FASN knockout results in significantly impaired SARS-CoV-2 replication that can be rescued with fatty acid supplementation. Together, these studies clarify roles for VPS34 and fatty acid metabolism in SARS-CoV-2 replication and identify promising avenues for the development of countermeasures against SARS-CoV-2.

Keywords

antiviral
autophagy
coronavirus
COVID-19
SARS coronavirus 2
fatty acid
membranes
phosphoinositol 3 kinase

Data and code availability

The published articled includes all datasets generated during this study. Raw data are available from the lead contact upon request. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Cited by (0)

4

Present address: Texas Biomedical Research Institute, San Antonio, TX 78227, USA

5

These authors contributed equally

6

Lead contact